Naltrexone depot implant in the treatment of co-morbid amphetamine and opioid dependence

ISRCTN ISRCTN88905555
DOI https://doi.org/10.1186/ISRCTN88905555
Secondary identifying numbers 84/24.9.2007
Submission date
25/10/2007
Registration date
30/10/2007
Last edited
21/08/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Jari Tiihonen
Scientific

Niuvanniemi Hospital
Kuopio
FI-70240
Finland

Phone + 358 (0)17 203 202
Email jari.tiihonen@niuva.fi

Study information

Study designA parallel double-blind, randomised, placebo-controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Scientific titleNaltrexone depot implant in the treatment of co-morbid amphetamine and opioid dependence: a double-blind, randomised, placebo-controlled trial
Study objectivesThe purpose of this study is to compare the efficacy of naltrexone depot implant (Prodetoxone) with placebo in reducing amphetamine and opioid use among patients having amphetamine (or methamphetamine) and opioid dependence.

As of 22/12/2009 this record has been updated in response to changes in the protocol. All updates can be found under the relevant field with the above update date. At this time, the anticipated start and end dates of this trial were updated; the initial trial dates were:
Initial anticipated start date: 10/11/2007
Initial anticipated end date: 31/12/2009
At this time, the sponsor was also updated; the initial sponsor of this trial was the National Research and Development Centre for Welfare and Health (STAKES) (Finland).
Ethics approval(s)Ethics approval received from the Independent Ethical Committee, St. Petersburg State Pavlov Medical University on the 24th September 2007 (ref: 84).
Health condition(s) or problem(s) studiedAmphetamine and opioid dependence (DSM-IV)
InterventionThe naltrexone arm will receive Naltrexone depot implant (Prodotoxone) (containing 1000 mg of naltrexone), and the placebo arm will receive an identical-looking placebo implant. The patient receive only one implant in the beginning of the study and the follow-up is 10 weeks for both arms.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Naltrexone (Prodetoxone)
Primary outcome measureCurrent information as of 22/12/2009:
1. Retention in the study
2. The proportion of urine samples, which are free of both amphetamine and opioids ("totally clean") during the follow-up. Missing samples are considered as amphetamine and opioid positive samples.
3. Improvement in Clinical Global Impression (CGI) during the follow-up

Initial information at time of registration:
1. Amphetamine concentration in the urine samples and proportion of amphetamine-negative urine samples in each arm, obtained each week
2. Proportion of opioid-dependent patients (assessed with naloxone challenge test) in each arm, measured at at week 10
Secondary outcome measuresCurrent information as of 22/12/2009:
1. The proportion of amphetamine free urine samples during the follow-up. Missing samples are considered as amphetamine positive samples.
2. The proportion of opioid free urine samples during the follow-up. Missing samples are considered as opioid positive samples.
3. Global Assessment of Functioning (GAF)
4. Number of days amphetamine used during follow-up
5. Adverse events

Initial information at time of registration:
Proportion of benzodiazepine-negative and cannabinoid-negative urine samples, obtained each week.
Overall study start date01/03/2008
Completion date28/02/2011

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants100 patients
Total final enrolment100
Key inclusion criteria1. Primary diagnosis of current Amphetamine and Opioid Dependence (Diagnostic and Statistical Manual of Mental Disorders, fourth edition [DSM-IV]), present for at least one year
2. Age between 18 and 50 years
3. Education as high school graduate or above
4. Negative urine toxicology and alcohol breath tests
5. Not currently on psychotropic medication
6. At least one relative willing to participate in treatment, monitor administration of medications, assist in follow-up, and provide outcome data
7. Stable address within St. Petersburg or nearest districts of Leningrad Region
8. Home telephone number at which the patient can be reached
9. Negative pregnancy test and use adequate contraception if of childbearing age
10. Willingness and ability to give informed consent and otherwise participate
Key exclusion criteria1. Clinically significant cognitive impairment, schizophrenia, paranoid disorder, bipolar disorder, or seizure disorder
2. Advanced neurological, cardiovascular, renal, or hepatic disease
3. Active tuberculosis or current febrile illness
4. Acquired Immune Deficiency Syndrome (AIDS)-defining illness
5. Significant laboratory abnormality such as severe anaemia, unstable diabetes, or liver function tests greater than 3 x above normal
6. Pregnancy
7. Pending legal charges with potential impending incarceration
8. Concurrent participation in another treatment study
9. Concurrent treatment in another substance abuse program
Date of first enrolment01/03/2008
Date of final enrolment28/02/2011

Locations

Countries of recruitment

  • Finland
  • Russian Federation

Study participating centre

Niuvanniemi Hospital
Kuopio
FI-70240
Finland

Sponsor information

National Institute for Health and Welfare (THL) (Finland)
Research organisation

Niuvanniemi Hospital
Kuopio
FI-70240
Finland

Phone +358 (0)17 203 111
Email jari.tiihonen@niuva.fi
Website http://www.thl.fi
ROR logo "ROR" https://ror.org/03tf0c761

Funders

Funder type

Government

Current information as of 22/12/2009:

No information available

Ministry of Health and Social Affairs (Finland) - National Institute for Health and Welfare (THL) and EVO-subsidies from Niuvanniemi Hospital

No information available

Initial information at time of registration:

No information available

Ministry of Health and Social Affairs (Finland) - Government of Finland, from National Research and Development Centre for Welfare and Health (STAKES) and EVO-subsidies from Niuvanniemi Hospital

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/05/2012 21/08/2019 Yes No

Editorial Notes

21/08/2019: Publication reference and total final enrolment added.